Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tuspetinib in Relapsed or Refractory Acute Myeloid Leukemia
NCT03850574Phase 2Recruiting
- Sponsor
- Aptose Biosciences Inc.
- Start
- Mar 2019
- Primary completion
- Nov 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 6
01
Overview
A Phase 2 trial of tuspetinib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Aptose Biosciences Inc.. Started Mar 2019; status: recruiting.
02
Drugs
tuspetinib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03850574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850574.